Morgan Stanley’s Astera Labs ALAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$815M Sell
1,686,491
-45,857
-3% -$12.2M 0.04% 393
2026
Q1
$190M Sell
1,732,348
-202,119
-10% -$28.8M 0.01% 983
2025
Q4
$322M Buy
1,934,467
+480,009
+33% +$80.3M 0.02% 708
2025
Q3
$285M Sell
1,454,458
-208,783
-13% -$34.3M 0.02% 746
2025
Q2
$150M Buy
1,663,241
+484,249
+41% +$38.3M 0.01% 1043
2025
Q1
$70.4M Buy
1,178,992
+296,604
+34% +$27.4M 0.01% 1513
2024
Q4
$117M Buy
882,388
+104,770
+13% +$9.83M 0.01% 1144
2024
Q3
$40.7M Buy
777,618
+329,658
+74% +$15.5M ﹤0.01% 2038
2024
Q2
$27.1M Buy
447,960
+370,356
+477% +$25.7M ﹤0.01% 2337
2024
Q1
$5.76M Buy
+77,604
New +$5.75M ﹤0.01% 3807

Other funds holding ALAB

Morgan Stanley's ALAB Position: Q2 2026 in Review

Morgan Stanley reduced its Astera Labs (ALAB) stake by 2.6% in Q2 2026, selling an estimated $12.2M and leaving 1,686,491 shares worth $815M. The position accounts for 0.04% of the portfolio, ranked #393.

Morgan Stanley first reported a position in ALAB in Q1 2024 and has held it in 10 quarters since. 988 funds tracked by Wall St. Rank hold ALAB as of Q2 2026.

  • Morgan Stanley held 1,686,491 shares of Astera Labs worth $815M as of Q2 2026.
  • Morgan Stanley sold 45,857 Astera Labs shares in Q2 2026, an estimated $12.2M.
  • Astera Labs made up 0.04% of Morgan Stanley's portfolio in Q2 2026, its #393 holding.
  • Morgan Stanley first reported a position in Astera Labs in Q1 2024 and has held it in 10 quarters since.
  • 988 funds tracked by Wall St. Rank held Astera Labs as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.